A sensitive real-time PCR based assay to estimate the impact of amino acid substitutions on the competitive replication fitness of human immunodeficiency virus type 1 in cell culture

Journal of Virological Methods

Volumn 189, Issue 1, 2013, Pages 157-166

  Liu, Yi ^a   Holte, Sarah ^b   Rao, Ushnal ^a   McClure, Jan ^a   Konopa, Philip ^a   Swain, J Victor ^a   Lanxon Cookson, Erinn ^a   Kim, Moon ^a   Chen, Lennie ^a   Mullins, James I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cell culture; Competition; HIV 1; Real time PCR; Replication fitness

Indexed keywords

COMPLEMENTARY DNA;

ACCURACY; AMINO ACID SUBSTITUTION; ARTICLE; CELL CULTURE; CONTROLLED STUDY; GENE MUTATION; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; VIFA GENE; VIFB GENE; VIROGENESIS; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN;

AMINO ACID SUBSTITUTION; CELL LINE; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; HIV CORE PROTEIN P24; HIV-1; HUMANS; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84875544727     PISSN: 01660934     EISSN: 18790984     Source Type: Journal    
DOI: 10.1016/j.jviromet.2012.10.016     Document Type: Article

References (34)

1. Ali A., Yang O.O. A novel small reporter gene and HIV-1 fitness assay. J. Virol. Methods 2006, 133:41-47.
2. Anastassopoulou C.G., Ketas T.J., Klasse P.J., Moore J.P. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:5318-5323.
3. Brockman M.A., Schneidewind A., Lahaie M., Schmidt A., Miura T., Desouza I., Ryvkin F., Derdeyn C.A., Allen S., Hunter E., Mulenga J., Goepfert P.A., Walker B.D., Allen T.M. Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. J. Virol. 2007, 81:12608-12618.
4. Brockman M.A., Tanzi G.O., Walker B.D., Allen T.M. Use of a novel GFP reporter cell line to examine replication capacity of CXCR4- and CCR5-tropic HIV-1 by flow cytometry. J. Virol. Methods 2006, 131:134-142.
5. Dimitrov D.S., Willey R.L., Sato H., Chang L.J., Blumenthal R., Martin M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 1993, 67:2182-2190.
6. Doyon L., Croteau G., Thibeault D., Poulin F., Pilote L., Lamarre D. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J. Virol. 1996, 70:3763-3769.
7. DuBridge R.B., Tang P., Hsia H.C., Leong P.M., Miller J.H., Calos M.P. Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 1987, 7:379-387.
8. Ellis G.M., Mahalanabis M., Beck I.A., Pepper G., Wright A., Hamilton S., Holte S., Naugler W.E., Pawluk D.M., Li C.C., Frenkel L.M. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drug-resistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J. Clin. Microbiol. 2004, 42:3670-3674.
9. Fernandez C.S., Stratov I., De Rose R., Walsh K., Dale C.J., Smith M.Z., Agy M.B., Hu S.L., Krebs K., Watkins D.I., O'Connor D.H., Davenport M.P., Kent S.J. Rapid viral escape at an immunodominant simian-human immunodeficiency virus cytotoxic T-lymphocyte epitope exacts a dramatic fitness cost. J. Virol. 2005, 79:5721-5731.
10. Garcia-Lerma J.G., MacInnes H., Bennett D., Weinstock H., Heneine W. Transmitted human immunodeficiency virus type 1 carrying the D67N or K219Q/E mutation evolves rapidly to zidovudine resistance in vitro and shows a high replicative fitness in the presence of zidovudine. J. Virol. 2004, 78:7545-7552.
11. Hubner W., McNerney G.P., Chen P., Dale B.M., Gordon R.E., Chuang F.Y., Li X.D., Asmuth D.M., Huser T., Chen B.K. Quantitative 3D video microscopy of HIV transfer across T cell virological synapses. Science 2009, 323:1743-1747.
12. Koval C.E., Dykes C., Wang J., Demeter L.M. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N+L100I by the nucleoside resistance mutation L74V. Virology 2006, 353:184-192.
13. Lalonde M.S., Troyer R.M., Syed A.R., Bulime S., Demers K., Bajunirwe F., Arts E.J. Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispecies. J. Clin. Microbiol. 2007, 45:2604-2615.
14. Liu Y., McNevin J., Cao J., Zhao H., Genowati I., Wong K., McLaughlin S., McSweyn M., Diem K., Stevens C., Maenza J., He H., Nickle D.C., Shriner D., Collier A.C., Corey L., McElrath M.J., Mullins J.I. Selection on the human immunodeficiency virus type 1 proteome following primary infection. J. Virol. 2006, 80:9519-9529.
15. Liu Y., McNevin J., Zhao H., Tebit D.M., Troyer R.M., McSweyn M., Ghosh A.K., Shriner D., Arts E.J., McElrath M.J., Mullins J.I. Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J. Virol. 2007, 81:12179-12188.
16. Ma J., Dykes C., Wu T., Huang Y., Demeter L., Wu H. vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. BMC Bioinform. 2010, 11:261.
17. Mammano F., Trouplin V., Zennou V., Clavel F. Retracing the evolutionary pathways of human immunodeficiency virus type 1 resistance to protease inhibitors: virus fitness in the absence and in the presence of drug. J. Virol. 2000, 74:8524-8531.
18. Martinez-Picado J., Martinez M.A. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo. Virus Res. 2008, 134:104-123.
19. Martinez-Picado J., Prado J.G., Fry E.E., Pfafferott K., Leslie A., Chetty S., Thobakgale C., Honeyborne I., Crawford H., Matthews P., Pillay T., Rousseau C., Mullins J.I., Brander C., Walker B.D., Stuart D.I., Kiepiela P., Goulder P. Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 2006, 80:3617-3623.
20. Martinez-Picado J., Savara A.V., Sutton L., D'Aquila R.T. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 1999, 73:3744-3752.
21. McClure J., van't Wout A.B., Tran T., Mittler J.E. Granulocyte-monocyte colony-stimulating factor upregulates HIV-1 replication in monocyte-derived macrophages cultured at low density. J. Acquir. Immune Defic. Syndr. 2007, 44:254-261.
22. Nijhuis M., van Maarseveen N.M., Boucher C.A. HIV protease resistance and viral fitness. Curr. Opin. HIV AIDS 2007, 2:108-115.
23. Petropoulos C.J., Parkin N.T., Limoli K.L., Lie Y.S., Wrin T., Huang W., Tian H., Smith D., Winslow G.A., Capon D.J., Whitcomb J.M. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 2000, 44:920-928.
24. Quinones-Mateu M.E., Ball S.C., Marozsan A.J., Torre V.S., Albright J.L., Vanham G., van Der Groen G., Colebunders R.L., Arts E.J. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 2000, 74:9222-9233.
25. Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Amer. J. Hyg. 1938, 27:493-497.
26. Resch W., Ziermann R., Parkin N., Gamarnik A., Swanstrom R. Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly. J. Virol. 2002, 76:8659-8666.
27. Rolland M., Nickle D.C., Mullins J.I. HIV-1 group M conserved elements vaccine. PLoS Pathog. 2007, 3:e157.
28. Sharma P.L., Crumpacker C.S. Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. J. Virol. 1997, 71:8846-8851.
29. Stekler J., Collier A.C. Primary HIV infection. Curr. HIV/AIDS Rep. 2004, 1:68-73.
30. Troyer R.M., Lalonde M.S., Fraundorf E., Demers K.R., Kyeyune F., Mugyenyi P., Syed A., Whalen C.C., Bajunirwe F., Arts E.J. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. AIDS Res. Hum. Retroviruses 2008, 24:235-250.
31. Troyer R.M., McNevin J., Liu Y., Zhang S.C., Krizan R.W., Abraha A., Tebit D.M., Zhao H., Avila S., Lobritz M.A., McElrath M.J., Le Gall S., Mullins J.I., Arts E.J. Variable fitness impact of HIV-1 escape mutations to cytotoxic T lymphocyte (CTL) response. PLoS Pathog. 2009, 5:e1000365.
32. van Maarseveen N.M., Huigen M.C., de Jong D., Smits A.M., Boucher C.A., Nijhuis M. A novel real-time PCR assay to determine relative replication capacity for HIV-1 protease variants and/or reverse transcriptase variants. J. Virol. Methods 2006, 133:185-194.
33. Wang J., Dykes C., Domaoal R.A., Koval C.E., Bambara R.A., Demeter L.M. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology 2006, 348:462-474.
34. Wu H., Huang Y., Dykes C., Liu D., Ma J., Perelson A.S., Demeter L.M. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J. Virol. 2006, 80:2380-2389.